SCHEMBL10072324

SCHEMBL10072324

Cc1cc(C(F)(F)F)cc(C2(C(F)(F)F)CC(c3ccc(C(=O)O)c4ccccc34)=NO2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.39
HPGD P15428 2/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
ADCY8 P40145 2/20 0.33
ADCY1 Q08828 2/20 0.33
ACLY P53396 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CCR2 P41597 3/20 0.31
LTB4R Q15722 2/20 0.31
LTB4R2 Q9NPC1 2/20 0.31
SYK P43405 1/20 0.31
SORT1 Q99523 4/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL872236 0.93 RXRA (0.34) TAS2R14HPGDRXRARXRBACLY
SCHEMBL10072323 0.91 CFTR (0.34) TAS2R14HPGDADCY8ADCY1HDAC3
SCHEMBL10072339 0.89 HPGD (0.35) HPGDSYKLMNAGLAALOX15
SCHEMBL870558 0.89 LTB4R (0.32) TAS2R14HPGDRXRARXRBCCR2
SCHEMBL30313890 0.89 ACLY (0.38) ACLYLTB4RLTB4R2LMNAGRIK1
SCHEMBL2780339 0.89 ACLY (0.38) ACLYLTB4RLTB4R2LMNAGRIK1
SCHEMBL10072325 0.87 GPR52 (0.37)
SCHEMBL10072326 0.86 HDAC3 (0.32) TAS2R14HPGDADCY8ADCY1HDAC3
SCHEMBL869874 0.85 CFTR (0.37) LMNA
SCHEMBL10316194 0.84 TYMS (0.35) HPGDTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404649-B2 Isoxazoline oximes as antiparasitic agents AH USA 42 LLC (US) 2013-03-26 US disclosed
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS CYP1A2, CYP3A7, CYP2E1 TAS2R14 2537/4885HPGD 1699/4885RXRA 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.